Nueva vacuna reduce casi a la mitad el riesgo de recurrencia del cáncer de piel

A groundbreaking new vaccine has been shown to reduce the risk of skin cancer recurrence by nearly half, according to a study released on June 1, 2026. The vaccine, developed by researchers at a leading medical institution, targets melanoma, the most dangerous form of skin cancer.

In clinical trials, patients who received the vaccine alongside standard treatment saw a 44% lower risk of their cancer returning compared to those who received standard treatment alone. The findings, published in a major medical journal, represent a significant advance in cancer immunotherapy.

Experts say the vaccine works by training the immune system to recognize and attack cancer cells specific to each patient's tumor. The study involved hundreds of participants across multiple countries, and researchers are now planning larger trials to confirm the results.

If approved, the vaccine could become a new standard of care for melanoma patients, offering hope to millions worldwide. The research was funded by grants from national health agencies and private foundations.